2021-03-31-accounts

THE BRAIN TUM•UR fUM•UR CHARITY ANNUAL REPORT AND ACCOUNTS 2020-2021

CONTENTS

1. Report of the Trustees

a. Strategic Report

b. Statement of the Trustees’ responsibilities

1. Independent auditor’s report

2. Statement of financial activities

3. Balance sheet

4. Cash flow statement

Page 3 12 40 41 45 46 47

N.B. Images throughout taken prior to the Coronavirus pandemic. 2

CHAIR’S REPORT

In reflecting on the Financial Year 2020/21, it will of course go down in history as being the year of the COVID-19 pandemic – a global crisis which continues to play havoc with countless lives. This crisis has heightened the needs of those with brain tumours, as well as straining NHS brain tumour services further, significantly slowing the pace of research and impacting on our own income and resources.

This year has been about pulling together in response to the pandemic, to support those in need while making sure we're in a strong position to pursue our goals in an altered world once the crisis abates.

My enormous gratitude goes to all those who've stood with us during this time to support those with brain tumours – whether personally affected, fundraisers, volunteers, researchers, clinicians, partner charities, heathcare providers, campaigners or the team at The Charity. Each of you has gone to extraordinary lengths to make a difference in this most challenging of years. Thanks to you, together we've supported thousands during this most isolating and testing of times; we've been able to maintain our commitment to our pioneering research programmes; and have been able to sustain innovative projects that'll accelerate our goals of doubling survival and halving the harm that brain tumours have on quality of life.

In addition to coping with the effects of the pandemic, I'm proud to share some of the progress we've made over the past five years in this report, across all areas of our strategy, ‘Defeating Brain Tumours’. As that strategy draws to a close, we used this year to consolidate that progress and renew our plans, in response to the heightened need for support and focussing our reduced resources during the pandemic, while pressing forward with long-term change. Our new transition strategy, ‘Leaning In’, provides the foundations for building upon our achievements, through what has been one of the most challenging periods in modern history. It aims to accelerate change in three ways: by ensuring the Best Care Everywhere through driving up standards; by harnessing the Power of Data to tackle inequality and evidence change; and by collaborating with all those who share our vision, hearing, strengthening and adding our voice to those Voices for Change, so we can support one another in coping with this devastating disease, raising funds and campaigning for a better future.

At the end of 2020/21, our CEO, Sarah Lindsell left The Charity after 10 years at the helm. Sarah joined The Charity when it was still quite small, although very ambitious, and built it into the formidable organisation it is today. Her passion and determination over the years played a vital part in taking us where we are, for which we thank her and wish her well for the future. I'm also most grateful to Dr. David Jenkinson, our Chief Scientific Officer, for stepping into the Interim CEO role following Sarah's departure and for so ably leading The Charity since then.

In September 2020, Angela Dickson MBE retired as a trustee after 23 years. Angela, with her husband Neil, founded The Samantha Dickson Trust in memory of their dear daughter who passed away from a brain tumour. The trust was one of the key founding charities which merged to become what's now known as The Brain Tumour Charity and, as one of our founders, Angela has worked tirelessly for our cause. I'm delighted that The Charity’s relationship with Angela will continue with her becoming our first Emeritus Founder Trustee.

3

I’m equally delighted that Robert Posner will also be taking on a new role with The Charity as Emeritus Trustee after stepping down from his position as a trustee earlier in the year. Robert also joined The Charity as part of the 2013 merger that created what's now known as The Brain Tumour Charity, having served as a trustee with Brain Tumour UK since March 2008. He has our sincerest thanks for everything that’s been achieved with his support.

I would like to also thank and pay tribute to my fellow trustees for their continual support and hard work. Trustees are often the unsung heroes in charities, giving their time freely and generously while having to oversee (particularly in the last year) some very stressful and challenging issues. The Brain Tumour Charity is blessed with having a board of Trustees that are talented, passionate and committed, and I'm deeply grateful for the unwavering support they provide in everything we do.

The achievements of the past and the potential of the future are only possible thanks to your continued support and we remain deeply appreciative of that gift. You've not only underpinned the sustenance and determination necessary over the last year but also provide us with the springboard and direction for the path ahead. I look forward to being a voice for change with you all, as we emerge with purpose from this crisis towards our shared vision of a world where brain tumours are defeated.

Jack Morris CBE

Chair of Trustees, The Brain Tumour Charity

4

CEO’S REPORT

The 2020-21 year has been one focussed on supporting the community through the pandemic. Not only were people less likely to come forward for a diagnosis, but treatments have been delayed and research halted, as NHS resources were diverted. It's been thanks to the help of amazing volunteers that we've been able to meet the increased demand for support this year, with the boosted team helping over 27,000 individuals directly (up 50%) - and over 1.2 million globally online (up 27% - in coping with their experience and navigating an NHS at full stretch. Sadly, at the same time, we've had to reduce our resources as, despite your inspiring fundraising efforts this year, the lack of big events meant that our income came under pressure. I want to publically recognise the selfless contribution made by those who left us this year to our long-term ability to serve the community.

We'd planned to share our new research strategy prior to the pandemic, based on wide consultation in 2019. Those plans have been postponed, but we're adapting them and will share them shortly, so we can continue to accelerate a cure. We did renew our overall strategy, Defeating Brain Tumours 2015-2020, as planned this year, although in a scaled down way, starting with an Impact Report. I'm delighted to introduce each section of this report with a taste of that impact as context, and links to where you can find out more.

Thanks to your support, the needle is shifting towards our goal of doubling survival: over the past five years, average life expectancy for those with high grade tumours increased by 5 months in the UK – the biggest percentage shift of any significant disease - representing countless celebrations and other precious memories. Momentum is building and our new strategy, ‘Leaning In’, will accelerate this further, reflecting the changed circumstances and our reduced resources but retaining our pioneering spirit and ambition.

The crisis has not stopped us in making progress aligned to this new strategy: in addition to growing the reach of our support, the community have shaped the development of a ‘step-by-step’ guide for patients that's now being used as UK best practice standard; we've mobilised a growing network of experts by experience – now over 700 people - whose voices are shaping our future direction; we've recruited a data science team to generate evidence to inform change; we've maintained the funding of our existing research programmes; and worked hard on awareness campaigns that matter the most to you.

As some will be aware, our outstanding CEO of 10 years, Sarah Lindsell, took the decision to move on during this year, once the new strategy was in place. On behalf of The Charity and wider community, we're deeply grateful for her inspirational and dedicated leadership over the past decade. That leadership transformed us into the global force we are today for championing justice, pioneering change, funding research and providing support and hope for those with brain tumours.

So this has been another year of change and challenge and it's only thanks to you that we can continue to represent hope for those most in need. As we close this tumultuous year, I'm deeply grateful for your ambition and passion which – together with the momentum of past years – we'll use to change the future for those with this brutal disease. Thank you for all that you've done and please continue to add your voice to ours so we can go further, together.

A cure can’t wait.

Dr David Jenkinson

Interim CEO and Chief Scientific Officer

6

7

ISPNO 2020

FOUNDERS WIN GLOBAL RECOGNITION FOR CHARITY ACHIEVEMENT

Neil and Angela Dickson have been named as the first recipients of a major global award from world leaders in the field.

They both set up the Samantha Dickson Brain Tumour Trust at their home in Dogmersfield following the death of their daughter in October 1996, just a few days before her 17th birthday.

The couple had discovered there was no charity dedicated to offering support for patients and families affected by a brain tumour, while research into the disease was almost non-existent. The Trust went on to become the largest dedicated brain tumour charity in the world. In 2013 it merged with two similar organisations to become what's now The Brain Tumour Charity. In 2014 the couple were both awarded an MBE. So far, we've committed more than £38 million to research into brain tumours - more than any other organisation of its kind in the world. We've supported around 32,000 people affected by the disease.

Now Mr Neil and Angela are to receive the newly-launched Paediatric Neuro-Oncology Community Service Award from the International Society of Paediatric Neuro-Oncologists. The award was presented to them at the virtual ISPNO 2020 annual conference today, the 14th December. Dr Koichi Ichimura, Chair of ISPNO2020, said Mr and Mrs Dickson had been the ‘strongest supporters’ of research into childhood brain tumours over many years.

“Through their endless dedication and tireless work, they have helped a great many researchers, patients and families across the years. The Chairs of ISPNO over the last 10 years agreed unanimously that Mr and Mrs Dickson deserve to be recognised at the highest level with this prestigious award, and we are tremendously honoured to nominate them.”

Neil, said: “Angela and I are immensely proud to accept this award from ISPNO. We could never have dreamt, in those early days after we lost Samantha, that her legacy would reach so far and so wide. When she was diagnosed with a brain tumour at the age of 14, there was absolutely no support mechanism for those diagnosed and research into the disease was almost non-existent. Through The Samantha Dickson Brain Tumour Trust we were able to change all that.

“In the first 10 years, we had two research breakthroughs which led to two new treatments for childhood brain tumours. Our work to raise awareness of childhood brain tumour symptoms culminated in the launch of the launch of the HeadSmart campaign, which has won five national awards. Since HeadSmart began, the average time taken to diagnose a childhood brain tumour in the UK has fallen from more than 13 weeks to 6.5 weeks.

“On the support side, we now have a substantial network throughout the UK and globally to help patients and their families. And The Brain Tumour Charity is still growing, investing in research around the world to accelerate progress towards our twin goals of doubling brain tumour survival and halving the harm caused by the disease.”

Sarah Lindsell, Former Chief Executive of The Brain Tumour Charity, said: “Since losing Samantha, Neil and Angela have worked ceaselessly towards ensuring that other families facing the shock of a brain tumour diagnosis are not left without help or without hope. This award from ISPNO recognises the very real difference they've made to so many thousands of people in the UK and around the world whose lives have been changed forever by this devastating disease.

“It's richly deserved and all of us at The Brain Tumour Charity are thrilled that their achievements have been marked in this way.”

9

OUR OBJECTIVES AND ACTIVITIES

The objectives of The Charity are to provide public benefit by:

• Relieving sickness and protecting good health by supporting research and publishing useful results of research into the nature, causes, diagnosis and treatment, as well as the social consequences of, tumours of the brain and central nervous system

• Relieving the suffering of people with tumours of the brain and central nervous system, their families and carers, through the provision of information and support

• Advancing the education of the public in all areas relating to tumours of the brain and central nervous system

The Charity’s aims to achieve these objectives through the following activities:

• A Cure Can’t Wait – This initiative is committed to funding leading research projects and programmes under the guidance of our Scientific Advisory Boards. All projects are reviewed annually to determine how they are performing against their stated objectives.

• Every Patient is a Research Patient – This aims to relieve suffering and support research by enabling all patients to contribute to research and clinical trials. We've created a pioneering app and databank BRIAN (Brain tumouR Information and Analysis Network) and we measure the number of patients who contributed to research.

• Early and Accurate Diagnosis – Working to reduce diagnosis times and improve accuracy which should relieve suffering and harm. This is achieved through different activities that raise awareness and assist early diagnosis. Improvements are measured by reduced diagnosis times and better outcomes.

• Equal Access to the Best Treatment and Care – By ensuring every person with a brain tumour has the same access to high-quality treatment, care and information we will reduce suffering. Activities such as publishing a Patient Guide, performing regular surveys and working with the Tessa Jowell Centres of Excellence will drive up standards of care.

• Improving Life Today – This advances education and relieves suffering by providing information and support to help every person navigate the healthcare systems. We measure our performance by the number of contacts we have and events we hold.

• United in our Battle to Defeat Brain Tumours – Leading and facilitating a community that works collaboratively to achieve all of our objectives by working more effectively together. Success in this area can be measured through mergers with other charities and the number of events held and participants attending.

PUBLIC BENEFIT

STATEMENT

The Trustees have considered the Charity Commission’s general guidance on public benefit and have taken it into account when reviewing The Charity’s aims and objectives and in planning its future activities. The Trustees are satisfied that the aims of The Charity are carried out wholly in pursuit of its charitable aims for the public benefit.

10

THE BRAIN TUM•UR CHARITY I (UKE CAN'T WAIT

StRAtEGIc REpORt

A CURE CAN’T WAIT

We’ll invest in forward-thinking, outcome-orientated and patient-focused research. We’ll bring about global collaboration to speed up the time it takes to turn discoveries into treatments and cures.

This initiative was driven by our 2015 research strategy, ‘A Cure Can’t Wait’. Since 2015, and under the guidance of our Scientific Advisory Boards, we have committed over £38m to leading research projects and programmes, resulting in a global, collaborative network of brain tumour researchers. You can see our full impact here , but in summary we have:

• Funded the discovery of new brain tumour knowledge, with our research leading to nearly 300 new research papers, tools and databases.

• Translated research into new or improved treatments, resulting in almost 30 new clinical trials, products, interventions and start-up companies focussed on improving outcomes, including pioneering partnerships with industry and the launch of ‘BRAIN MATRIX’, a UK-wide platform study designed to accelerate the development and delivery of brain tumour clinical trials.

• Stimulated new research into brain tumours, with our investment of £38m attracting £43m in collaborative funding from other investors and a further £46m in follow-on funding for these pioneering projects.

12

We maintained funding towards our existing research commitments, spending £6.5m this year (highlights below). This was less than we wanted because of COVID-19 and the fact that researchers were diverted to fighting the pandemic, with many laboratories forced to close or operate at reduced capacity globally. However, we were the only major funder to commit new funds to research into brain tumours this year, awarding 11 new grants worth £4.8m. We've also been planning for the future, in line with our new strategy, by using the Power of Data, building our capability to use data from research to provide evidence for change. We'd already consulted widely on an updated research strategy, prior to the pandemic, and will share this shortly as research restarts.

13

HIGHLIGHTS OF 2020/21

NEW RESEARCH PARTNERSHIP WITH THE OLI HILSDON FOUNDATION

The Foundation was set up to fund research into brain tumours in loving memory of Oli Hilsdon, who lost his battle with glioblastoma (GBM) – an aggressive grade 4 brain tumour – in January 2019, just 10 days before his 27th birthday. The Foundation’s promising partnership with The Brain Tumour Charity will accelerate research into GBM in the search for a cure.

The Oli Hilsdon Foundation believes that exceptional breakthroughs come from exceptional research - and breakthroughs are desperately needed in brain cancer. Our collaboration with The Brain Tumour Charity allows us to invest 100% of our resources in the most effective way, committing to world-class, pioneering projects that offer the best chance of success and will lead to change.

• The Oli Hilsdon Foundation

PROMISING RESEARCH ON LOW GRADE GLIOMA DRUG FOR CHILDREN

Our researchers from The Everest Centre published new results in 2020 that show the drug trametinib can stop tumour growth in some children with low grade brain tumours, and in some cases the tumour was seen to shrink as well. This highlights the need for more prospective trials (analysing information as the treatment is given) to test promising new treatments for these children.

14

IMPROVED UNDERSTANDING OF CHILDHOOD BRAIN TUMOURS

Our funded researcher Todd Hankinson and his team at Children’s Hospital Colorado have studied biological differences between paediatric and adult adamantinomatous craniopharyngiomas (ACP) tumours. They concluded that there were no differences in the presence of these targets between age groups. This exciting news means that in the future, identification of targeted therapies and implementation of these into the clinic may be relevant for both children and adults.

Research into ACP biology has been overlooked and nearly no novel therapies have been introduced for over 50 years, resulting in patients having the lowest quality of life. This research has massive potential for patient benefit.

• Dr Todd Hankinson, University of Colorado, USA

NEW WAYS TO TEST DRUGS FOR CHILDHOOD BRAIN TUMOURS

Funded researcher Till Milde and his team from the Hopp Children’s Cancer Center Heidelberg (KiTZ) have developed a new test system that enables them to rapidly test different combinations of drugs and measure their effect on paediatric low-grade glioma cells grown in the lab. Using this test system, the researchers were able to identify a group of promising candidate substances that inhibit the ‘MAPK’ signalling pathway, thereby suppressing the growth of the cancer cells. These results are currently being used by the KiTZ Clinical Trial Unit to prepare a phase I/II clinical trial.

15

PREDICTING RELAPSE AND IMPROVING TREATMENT FOR MEDULLOBLASTOMA

Research led by Professor Steve Clifford from Newcastle University has revealed that experts can now identify the time, nature and outcome of medulloblastoma relapse from the biology of the disease at diagnosis and the initial therapy received. This breakthrough will help doctors to identify which patients are most at risk of continuing problems with the disease, giving them the opportunity to fine-tune treatment and surveillance to improve quality of life after relapse for these children.

IDENTIFYING DIFFERENCES IN GLIOBLASTOMA CELLS

Our funded researchers Drs Stuart Smith and Ruman Rahman at the University of Nottingham Biodiscovery Institute, were able to use a substance called 5-ALA to separate cells found at the core of a glioblastoma (GBM) from the cells found at the edge of the tumour and which infiltrate into the surrounding healthy brain tissue. This enabled them to uncover key differences between the two cell populations. One of the differences the team found was that a gene called SERPINE1 was only expressed in the infiltrating cells but not in the core cells; when these cells were treated with a drug targeting SERPINE1, they lost their infiltrative properties. These exciting findings give hope towards developing treatments that'll target invasive GBM cells.

RESEARCH WEBINARS DURING THE PANDEMIC

Over the year, we've curated and facilitated a series of 60-minute webinars for researchers. The webinars feature experts in the brain tumour field speaking on a wide range of current topics and have helped to keep the research community connected and engaged during the pandemic. So far we've held 10 webinars involving nearly 1,000 researchers. This has resulted in us reaching 904 researchers who are new to us and who'll therefore receive information about our research strategy and funding opportunities.

This format makes it so much easier to hear, and share, new data and explore new avenues as they arise, which is sure to accelerate progress.

-Dr Lucy Stead, Head of Glioma Genomics, Leeds Institute of Medical Research, UK

CANNABINOID DRUG TRIAL

To enable us to try to continue investing in new, world-class research to improve survival for adults affected by a glioblastoma, we're piloting a new research funding mechanism. There's considerable interest in both the lay and scientific communities relating to the activity of cannabinoids in brain tumours with the view that cannabinoid-based products not only help to relieve the symptoms of a brain tumour but also have a positive impact on survival. In February 2021, we launched an exceptional grant round with a view to funding a phase II/III clinical trial of cannabinoids in the treatment of high grade gliomas in adults later this year. This was approved by our Scientific Advisory Board, and we're now seeking to raise the funds via an urgent fundraising campaign before the trial can begin.

16

EVERY PATIENT IS A RESEARCH PATIENT

We’ll make sure every patient is able to contribute to research and clinical trials, as this gives them faster access to treatments, better care and the opportunity to help defeat this disease.

Since 2015, we’ve launched our pioneering app and databank, BRIAN ( B rain tumou R I nformation and A nalysis N etwork), to harness the power of patient data for those affected and for researchers. We encourage people to participate in research not only through BRIAN but also through our growing Involvement Network (see below), our step-by-step guide to brain tumour diagnosis and treatment, and on social media. Our patient survey found that, in 2020, 42% of people contributed to research or discussed options – such as bio-banking or molecular testing - compared to just 24% in 2016. The clinical trial options for brain tumour patients remain low compared to other cancers, but we're taking steps to address this with the BRAIN MATRIX clinical study platform – see below. For more information on our impact in this area, see here .

We're building on this progress by developing the BRIAN project, using the Power of Data to support those using the app and to accelerate research. We're also funding the BRAIN MATRIX platform study and driving forward best practice in the treatment centres so that more people are offered the chance to participate in research, including routinely having molecular testing of their tumour.

18

HIGHLIGHTS OF 2020/21

OPENING OF THE BRAIN MATRIX CLINICAL TRIAL PLATFORM

One of the most recent significant developments in research and care for people with a brain tumour is the opening and recruitment of the first patients to the Tessa Jowell BRAIN MATRIX. Set up and funded by The Brain Tumour Charity, BRAIN MATRIX provides a platform to trial precision medicine, using its multicentre ’portal’ protocol to recruit patients and enable enrolment into biomarker-driven trials. All participants in BRAIN MATRIX will have their tumour tested in a lab to uncover its molecular profile. In addition to the information about molecular changes in the tumour, imaging, treatment and other clinical and quality of life data from each participant will be collected and analysed at a central hub. This will allow for more powerful analysis than ever before. By having molecular profiles ready-to-hand, future trials will be a step ahead and people will know, sooner, if new experimental treatments could be appropriate for them. BRAIN MATRIX represents a significant step towards providing the infrastructure to facilitate the opening of glioma clinical trials in the UK as well as ensuring the feasibility of genetic testing in a clinically relevant timeframe.

BRIAN

BRIAN is our ground-breaking app and databank that’s revolutionising the way we tackle brain tumours. It’s the biggest data collection project in the history of research into this disease, and it’s powered by those who are personally affected. BRIAN not only helps people with a brain tumour take more control of their diagnosis but will help shape the future of research into brain tumours.

First, BRIAN supports people by letting them track symptoms, appointments, moods and more, quickly and easily logging their experiences and getting the knowledge they need to make more informed decisions. Then, this anonymised data will go to world-leading scientists, who’ll use it to kickstart vital research into brain tumours. Every single experience logged adds hope for the future and accelerates progress towards a cure.

We were thrilled to launch BRIAN as a mobile app in December 2020 – and since then it’s gone from strength to strength. As of writing, we now have over 5,000 sign ups, a fantastic stride forward in our drive for better data availability, better care and improved quality of life for people diagnosed with a brain tumour.

BRIAN helps you stay on top of your diagnosis and treatment and it actually helps you to learn from other people’s experiences, make better informed decisions about your own treatment, and empowers you as a patient or as the carer. And I think that’s a really positive thing in the very difficult world that you’ve found yourself in.

Knowing that Silas’s data is now in BRIAN, and might one day hopefully contribute to the advancement of treatments for brain tumours, helps to give his life meaning, which is really comforting. And I think the important thing to remember is that the more data that is in BRIAN, the better BRIAN becomes.

-Sarah Pullen, whose son Silas died from a brain tumour in 2013 at 11 years old

19

Working with Lorcan and The Brain Tumour Charity has been such a positive experience. Our members were provided with an evening of informed advice, debate and up-to-date medical knowledge, delivered in an easy-to-understand manner. Our members are already asking when the next event is!

-Sali Davis, Chief Executive of Optometry Wales

20

EARLY AND ACCURATE DIAGNOSIS

We continue to work to reduce diagnosis times and improve accuracy of diagnosis so that brain tumours are treated earlier, with the best possible treatment at the right time.

Our key impact over the past few years has been through our HeadSmart campaign, which has helped to reduce childhood diagnosis times from 13 weeks (prior to the strategy) to 6.5 weeks, making a difference to thousands of children. Another success since 2015 has been the progress made in access to biomarker testing, which is critical to getting appropriate treatment for a tumour. Testing is now available to all children following our pilot scheme, and an increasing number of adults (up from 6% in 2016 to 30% in 2020). Our main challenge has been in adult early diagnosis, which we know from our ‘Life with a brain tumour’ research, and anecdotally, to be an issue, with a high proportion of diagnoses following an emergency admission.

The Charity commissioned research to understand this better and the results included an improved understanding of, and evidence for, symptoms of brain tumours in adults. This year, we are using this knowledge to develop a symptom awareness campaign due to launch post COVID-19. Our HeadSmart campaign also continues, with a move away from physical HeadSmart cards to digital campaigning by the Voices for Change in the community that care deeply about this issue. Also, as we know that many people are diagnosed via their optician, we've been working to raise awareness of brain tumours within that sector (see below).

HIGHLIGHTS OF 2020/21

ADULT EARLY DIAGNOSIS CAMPAIGN

With little to go on but a gut feeling that something is wrong and some disconnected symptoms, our research shows that many adults are unable to make sense of what is happening, sent home multiple times when trying to get help, misdiagnosed and sometimes accused of exaggerating their symptoms by baffled healthcare professionals. This delay – commonly months and often years - causes real anxiety and gives the tumour time to grow so that, when the diagnosis finally comes, the outlook can be poorer and key abilities, like sight, can be put in jeopardy. Our research has identified the common signs and symptoms of a brain tumour and we're prioritising the roll-out of an adult symptom awareness campaign, building on the success of our HeadSmart campaign for children’s symptoms, as soon as the impact of the pandemic declines a little.

OPTICAL ENGAGEMENT

We've been hosting a range of virtual events to raise awareness of our work and the vital role optometrists, dispensing opticians and students can play in brain tumour diagnosis. This year, we've trained over 3,600 optical professionals in 41 training webinars ranging from 8 to 400 people, and enabled these professionals to play their part in early diagnosis.

21

EQUAL ACCESS TO THE BEST TREATMENT AND CARE

We’re working to ensure every person with a brain tumour has the same access to high-quality treatment, care and information regardless of postcode, age or tumour type.

Since 2015, we've published a Patient Guide to raise awareness of good practice and carried out numerous campaigns to close the gaps in care, Our regular patient surveys show significant increases since 2015 in access to key services such as a holistic needs assessment (13% increase); biomarker testing (24% increase); and the contact details of a key worker (19% increase). We also campaigned for 5-ALA (the ‘pink drink’) to be available for all patients undergoing surgery, to improve the accuracy of surgery. For more details see here .

This year, we've strengthened the framework for making sure everyone has access to the best care. Shaped by experts by experience, we've upgraded both our understanding of best practice and the scope of our surveys for people to give feedback on those standards. Our resulting excellence standard now underpins our support offer and the related and comprehensive suite of Improving Brain Tumour Care Surveys gathers feedback and helps us drive standards higher, with thousands starting to share their experience using these surveys this year. We'll use this information and evidence to drive further progress in the future.

HIGHLIGHTS OF 2020/21

IMPROVING STANDARDS OF TREATMENT

During the year we worked to upgrade our Patient Guide into a standard for excellence, shaped by experts by experience. The resulting standard is set out in our step-by-step guide to life with a brain tumour and forms an integral part of the support we provide online and face to face. At the same time, we developed a series of Improving Brain Tumour Care Surveys to get timely feedback on the application of those standards

22

across the UK and across six areas of care. These surveys have already been completed by thousands of people going through treatment and we've just shared the first findings with the treatment centres as part of our mission to improve care across the UK.

I found out I had a meningioma eight years ago following a sudden seizure at home. While the initial care provided in my local A&E was exemplary, the subsequent poor communication and inability to speak with any kind of specialist for several days meant I felt completely abandoned and terrified about what was happening to me. It doesn't need be like this for others.

The Brain Tumour Charity uses a series of short, easy-to-complete surveys to gain invaluable data and insights from those who have a tumour diagnosis. This information is then used to help highlight where treatment centres are performing well and also where standards of care can be improved."

-Neil Munn

TESSA JOWELL CENTRES OF EXCELLENCE

Our Excellence Standard now sets the bar for treatment centres applying to become Tessa Jowell Centres of Excellence: a programme run by the Tessa Jowell Brain Cancer Mission, of which we are a founder member. We can confirm that nine treatment centres were designated as Tessa Jowell Centres of Excellence with six more working towards the standard. We continue to work with the Mission, with our Involvement Network and with thousands completing the Improving Brain Tumour Care Surveys to raise standards and identify gaps.

23

IMPROVING LIFE TODAY

We provide information and support to help every person to navigate the system and improve their quality of life.

Looking back, we commissioned ‘Life with a brain tumour’ research in 2015 to find out what life was really like for those affected by a brain tumour diagnosis. This was the most comprehensive study of its kind globally and the results were compelling - please refer to the reports for the detailed impacts. Our services have grown over the past five years, driven by these findings. We've also made much more information available for self-service via our website, have award-winning information sheets on a wide range of topics from brain tumour types to how to cope after a diagnosis, set up a Benefits and Money Clinic, established a relationship support partnership and are now using BRIAN to take this support further. For more on our impact see here.

During 2020 we developed The Excellence Standard (see above) – an evolution of our original Patient Guide – which is now woven into our support. Our service offer now spans: digital support through the website and BRIAN app, with email support journeys and interactive tools; advice line through phone, email, live chat and social media, with a dedicated service for adults, young adults and children and families; specialist partnerships delivering a Relationship Support Service and Benefits and Money Clinic; and peer support through 11 support groups, virtual events and podcasts.

Overall, our support services grew significantly this year in response to the pandemic. 1.2 million people used our website support pages (an increase of 27% from last year); peer support through online groups continued to grow with 20,015 members across 11 support groups (up 50%); and calls to our advice line were up 50% to 3,792 calls with longer, more complex and more emotional support required. To help meet this demand, we turned to the community, who responded amazingly in volunteering their experience and time – fully trained and supported by us - in many ways including monitoring online groups and answering support call lines. Our thanks go to each and every one of them.

We'll build on this going forward, using our combined voices for change to support each other and reach more people in need.

24

HIGHLIGHTS OF 2020/21

SUPPORT DURING THE PANDEMIC

As the pandemic spread, we coordinated all our support and managed spikes in demand by creating a comprehensive coronavirus (COVID-19) hub on the website. This hub had 40,500 visits and 4,300 video views in its first two months and now 105,000 views over the year. People asked us for help with: understanding and accepting changes to treatment; assessing vulnerability and what isolating measures to take; thinking about treatment choices if infected with coronavirus; and coping practically and psychologically with isolation. We sourced responses from leading experts, uploading over 15 videos on the website, to help answer questions from the community while official communications caught up.

VIRTUAL EVENTS

Out of necessity, our support events went online this year, with over 160 people joining us (for an average of almost four events each), including family events, young adult events, phone support groups, and events for carers and adults. We also ran a number of Facebook Live events for several online support groups. Although this was a significant decline in attendance than for physical events (with over 70% fewer people than last year), virtual events do enable greater accessibility and we will make this option a permanent fixture long term.

The reason I joined was because my friends don’t understand what I go through, I don’t feel like I can open up to them in a way that I could for someone who understands. People can give me support and advice and I can do the same and it’s just a very nice feeling of community and feeling that you’re not alone; it’s a reassurance that other people know what you go through.

• A teenager who took part in our Online Meet Ups for Teenagers

It was lovely to meet new people, hear their stories and gauge others’ experiences of scans etc. during and after lockdown.”

• A participant in our Young Adults’ virtual meet ups

25

OUR YOUNG AMBASSADORS

Our Young Ambassadors are an integral part of The Brain Tumour Charity, helping us raise awareness of brain tumours and passionate about changing the future for those affected. The two-year Young Ambassador programme is for young adults aged 18-25 and we currently have 23 Young Ambassadors along with a team of Young Ambassador Mentors. As well as campaigning and supporting other teenagers and young adults affected by a brain tumour diagnosis, their ideas and input have been vital in shaping our Young Adult Service and developing our resources and we thank them all.

Through the Young Ambassadors programme I've had support that I never knew I needed. I've met the most wonderful group of people who inspire me every day. For the first time I was able to speak to someone who'd been through the same things I'd been through, and I realised all the feelings I had were OK, they were normal. It was like having a huge weight lifted off my shoulders, and finally, I've come to terms with what happened.

• Georgia

26

UNITED IN OUR BATTLE TO DEFEAT BRAIN TUMOURS

We will lead and facilitate a community that works collaboratively. We value everyone’s contribution.

Over the past five years, we’ve worked hard to bring an historically fragmented community together to defeat brain tumours. For those personally affected, we’ve built our advocacy and research network communities – with our amazing Young Ambassadors and the Research Involvement Network as key highlights. Specific events, such as The Twilight Walk and young adult meet-ups as well as our online peer-support communities and media stories, are all established as platforms for bringing people together and demonstrating impact. The development of funding partnerships is now central to our research and fundraising plans and our culture going forward - and have helped attract a further £89m directly from our own £38m of research spend since 2015. Please see here for more details.

This year, we've leant into the community further to continue, in line with our new strategy, to make an impact with our restricted resources. For example, we've brought all of our volunteer groups together under one Involvement Network; we've developed different ways to help our amazing supporters fundraise in a pandemic; we've welcomed new named funds (Supporter Groups) to The Charity; and we've merged with another UK charity to provide better meningioma support services. We'll build further on mobilising, combining and amplifying these voices for change going forward.

HIGHLIGHTS OF 2020/21

THE TWILIGHT WALK GOES VIRTUAL!

Sadly, The Twilight Walk could not go ahead due to the pandemic but we instead supported our amazing community in doing their own socially distanced walks during October and November 2020. This was a great success, thanks to the inventiveness and persistence of so many, with over 500 supporters taking part, raising over £300k between them.

2020 had always felt like it would be my year to take part and I wasn’t going to let the coronavirus pandemic stop me from doing that. It's been amazing for me to be back outside and to be completing the challenge finally. This is something that I always wanted to do – particularly to help raise awareness of and fund research into more rare brain tumour types like my own to help others like me.

• Sadaf

MERGER WITH MENINGIOMA UK

Meningiomas are the most common form of brain tumour in adults, accounting for around one in three of those diagnosed. The vast majority of meningiomas are low grade (non-cancerous) but they can cause significant health problems and damage to quality of life.

In 2020 we merged with Meningioma UK, consolidating our resources in a drive to improve services and outcomes for everyone affected by a brain tumour. Meningioma UK was founded in 1998 by Ella Pybus and Dr Caroline Rutgers, both of whom had been diagnosed with a meningioma. The charity focused on offering support and information to people affected by a meningioma. Following Dr Caroline Rutgers’ death, Ella Pybus remained at the helm of Meningioma UK until the decision to merge with The Brain Tumour Charity.

27

Our community was always at the heart of this decision. Together, with unified resource and vision, we'll be able to support more of, and do more for, the thousands of families whose lives are shattered by a meningioma diagnosis. This merger will build on the successes of the two charities and create a stronger, more powerful voice for change in the future.

• Ella Pybus

This merger is extremely exciting news. Creating larger communities that work together to advance understanding and treatment of rare diseases is critical. The merger will accelerate progress, without doubt; driving new research and improving clinical practice, allowing the voices of many, not a few, to be heard.

• Professor Richard Gilbertson

INVOLVEMENT NETWORK

During the year, we called on members of the community with personal experience of brain tumours to join us, as people who are passionate about improving outcomes for everyone affected. Supported by us, these champions represent the brain tumour community in shaping our work and direction, using their own experiences as well as taking into account the issues and challenges that affect the wider community. To date, over 700 people have joined the Involvement Network as influencers, with 20 taking on a formal volunteering role at The Charity to directly input into the way we do things. We look forward to working together to change the future!

FINANCE REVIEW

The global pandemic, had a severe impact on The Charity’s finances and activities throughout the financial year. Income fell 26% (£3.0m) to £8.3m compared to the previous year due to the pandemic and would've fallen further were it not for the generosity of the community.

The fall in income necessitated difficult decisions to control costs, including reducing the size of the team and ceasing or delaying avoidable expenditure. While doing this, priority was given to maintaining our research commitments and supporting the community, many of who needed our help more than ever as they had to cope with the impact of the pandemic both directly in their lives and due to the care they were receiving from health services being under severe pressure.

Where possible The Charity made use of the Coronavirus Job Retention Scheme, furloughing staff rather than losing them.

28

INCOME

Our funding comes through a diverse portfolio of income streams, with no reliance on any one stream. This provides greater security in funding multi-year research commitments.

The nature of the pandemic, with the main measure to control it being social distancing measures for the duration of the financial year, meant that face-to-face events were most heavily impacted. Mass social gatherings such as marathons, as well as smaller gatherings like cake sales or corporate fundraisers, were postponed or cancelled. Similarly fundraising dependent on travel such as sponsored activities, most notably Everest in the Alps, could not take place. Of the £3.0m fall in income, £2.5m is attributable to the reduction in Events, Community Fundraising, Celebrity Foundations (the Lewis Moody Foundation) and Everest in the Alps. The fact that this fall is not larger is thanks to the generosity and ingenuity of our supporters and fundraisers who switched to virtual events or new forms of giving to continue to raise money.

The Charity achieved an income of £8.3m against a budget of £8.0m which was considered an excellent result in the circumstances. The budget was set taking allowance of the pandemic and was 40% lower than it would otherwise have been.

The Charity made use of the Coronavirus Job Retention Scheme and £329k of grants from the scheme is included in "Other Income".

29

EXPENDITURE

Expenditure in the year reduced by £1.2m to £11.3m. The reduction was necessitated by the restriction of activities caused by the pandemic as well as a need to reduce expenditure given the fall in income and uncertainty due to the pandemic.

We are a research charity and funding quality research is vital to us achieving our ambitious objectives. In the year we prioritised funding of research projects. For that reason we both committed to 11 new projects at a cost of £4.8m over the coming years, and maintained funding to our existing projects with a total research spend this year of £6,644,000, slightly exceeding last year’s £6,567,000.

Other than in research, in other areas spending was down on last year as a response to the pandemic. General overheads were reduced and staff numbers and costs fell. Fundraising spend was down £0.5m to £1.7m as physical events could not take place and had to be deferred or became virtual. Expenditure on patient support reduced £0.6m to £2.1m despite the level of support via calls and on-line increasing. You can read more about this and our other achievements in the year on pages 24 to 26 of this report.

The Charity aims to spend at least 80p of every pound of expenditure on its charitable objectives. In the year to 31 March 2021 we managed to spend 84p as we continued our investment in quality research.

The Charity has one subsidiary, TBTC Trading Limited. The subsidiary, which is wholly owned by The Charity, carried out non-charitable retail trading activities for the benefit of The Charity. During the year, TBTC Trading Ltd made a profit of £21k which is to be donated to The Charity.

INVESTMENTS AND CASH

The COVID-19 pandemic caused considerable volatility in world-wide stock markets. At the end of the previous financial year The Charity’s investments were valued £12.0m after booking a loss of £1.8m in that year. In the financial year ended 31 March 2021 The Charity’s investments recovered this loss and increased further in value, with a gain of £2.7m in the year, such that they ended the year at a value of £14.7m. This exceeded the budgeted gain of £0.5m. Cash held as at 31 March 2021 was £5.0m.

RESERVES POLICY

COVID-19 has had a significant impact on The Charity’s income in the financial year to 31 March 2021 and it will continue to impact the year to 31 March 2022. Before the outbreak of COVID-19 the reserves policy of The Charity was to maintain unrestricted funds of at least six months’ operational costs to ensure the longterm sustainability of our services for our beneficiaries and to support our research commitments. The annual operational cost is about £5.9m. The level of total Funds at 31 March 2021 was £6.9m, consisting of unrestricted

30

general reserves of £1.8m, designated of £1.6m and restricted of £3.5m. After deducting the value of functional fixed assets, Free Reserves available are £1.4m.

The restricted and designated reserves are earmarked for use in the next two financial years. As a result of COVID-19, The Charity’s new reserves policy until 31 March 2023 is to have total reserves in excess of six months’ operational costs. As at 31 March 2021, the actual cover was 13.9 months.

At 31 March 2021, we had unaccrued but committed research expenditure totalling £13.7m which was subject to the satisfying of our ongoing monitoring requirements and expected to fall due over the next five years. The investments and cash at 31 March 2021 (which are all liquid) were £19.6m.

Our Supporter Groups typically express a preference over how the funds they raise should be spent. These preferences usually include our research or support activities and The Charity has earmarked these funds for future specific projects in the next two financial years. Income raised by these Supporter Groups is designated by the Trustees for the activities identified by each group.

From time to time, The Charity may hold accumulated reserves, which are intended to be utilised to commission further research and to cover existing research commitments. Accumulated funds are invested in accordance with The Charity’s investment policy.

The Finance Committee meets at least three times a year to review income, expenditure and all other financial issues, including risk, and reports to the main Board of Trustees.

INVESTMENT POLICY

The investment of funds is controlled by the Trustees who've appointed The Charity's Finance Committee to implement the Trustees' investment decisions. Albert E Sharp and Smith & Williamson have been appointed to manage the investment of any surplus liquidity we may have from time to time.

The mandate agreed with the investment managers is to hold a mixture of good quality cash proxies, government gilts and other fixed income securities, together with some equity exposure, with the objective of generating a balance between capital growth and income generation over the investment cycle. All investments are liquid. In reaching investment decisions, the Trustees consider the cash position of The Charity and our projected short and medium term cash needs. Investment manager performance is measured against established market benchmarks suitable for each investment class.

Overall, investment decisions are designed to produce the best financial return, within an acceptable level of risk, and also to maintain the value of funds in real terms, so far as practical. At the year end, The Charity had a £14.7m portfolio of UK equities, fixed interest securities, mixed funds, alternative investments and cash. In a volatile year for investments due mostly to COVID-19 the portfolio generated income of £355k and a valuation gain of £2,497k.

EMPLOYEES

The Charity operates an equal opportunities recruitment policy. The Remuneration Committee is responsible for overseeing The Charity’s pay and reward structures for all staff. The Remuneration Committee is also responsible for setting senior management salaries annually; having taken account of skills and experience, pay levels in similar organisations and the achievement of personal objectives and living The Charity’s values.

The long-term success and performance of The Charity is directly linked to the talents, motivation and accomplishments of our employees. We recognise the importance of developing our employees and focus on building organisational capability through first recruiting great people, then building high levels of relevant skills and knowledge through our High Performing Team programme. Staff motivation is fostered by providing an environment where work is stimulating and rewarding and a high level of collaboration across the organisation is encouraged.

The work we do wouldn’t be possible without the incredible contribution we receive from our volunteers. We currently have 1028 active volunteers across the UK, which has grown from 818 last year, who support in

31

different roles within the organisation. Voluntary activities include: supporting community fundraising activity, attending challenge events, campaigning, reviewing information resources for those diagnosed with a brain tumour, sitting on the panel who decide which research we fund and supporting different projects in our head office.

RISK FACTORS

The Trustees have considered the major risks to which The Charity is exposed. They have reviewed those risks and established systems and procedures to manage them such that they are part of the senior leadership’s regular management focus. The Finance Committee reviews governance and risk during each year and makes recommendations on best practice to the Trustees. The principal risks and uncertainties facing The Charity, and how we endeavour to mitigate these, are:

• That we fail to secure adequate income. We've developed our detailed fundraising strategy, intended to widen the balance of our portfolio of fundraising activities. We've invested in our people and systems to increase our fundraising capability. We measure fundraising performance against budgets and forecasts. We maintain at least six months of reserves. We have no overreliance on any one income stream and generally 40% of our income for the year is known income at the start of the year. The investment in CRM systems helps optimise stewardship plans.

• That we're not able to commission enough high-quality research projects. We're developing our engagement with the brain tumour research community, and working to build capacity in the sector. We're also looking at alternative research models. In addition, we've extended funding globally and put significant emphasis on building relationships with key researchers.

• That we become affected by damage to our reputation, or by negative sentiment in the charity sector. Entering and winning charity sector awards is a strong mitigation factor in this area. We also manage reputation risk through staff training and effective HR and volunteer policies. We monitor social and traditional media to inform us of factors impacting The Charity and the wider sector. We continue to be transparent and trustworthy in providing effective communications with donors, stakeholders and other key groups.

• That our IT infrastructure is not adequate to support our activities. We continue to invest and develop improved IT platforms and provide suitable training for our staff. Our IT infrastructure is hosted and managed externally by an IT solutions company.

• That we're the victim of cyber-crime. We outsource our IT hosting to a third party who meet the ISO 27001 Standard for datacentres, and ensure that we have leading-edge malware protection and cyber security. Online banking arrangements include double authorisation of all transactions and the use of random number generating security devices. All websites use SSL technology. In addition, we have cyber insurance policy.

• That we're impacted by a global pandemic, just like COVID-19. We have an incident management plan and this was implemented in March 2020, with the priority of helping those most vulnerable in the community to deal with the anxiety and practicalities caused by the pandemic. We've set up The Charity so that everyone can work from home, we've introduced virtual fundraising activities and have been able to furlough staff members if necessary. By having a six months’ reserve policy we should be able to ride out any significant adverse financial impact on The Charity.

32

GOING CONCERN

The Trustees have reviewed The Charity’s annual budget and five-year projection, which are updated on an annual basis, as well as the principal financial risks.

The COVID-19 pandemic impacted The Charity’s community, finances and activities, as described in various sections of this report, including the Finance Review. It impacted on the daily activities of The Charity as employees had to work remotely. The Charity was able to rapidly adapt to these changes, with systems that facilitated remote working, cost saving measures utilising the Coronavirus Job Retention Scheme and adapting to virtual fundraising events.

The Charity expects income to slowly recover in the following 12 months as the worst effects of the pandemic subside. Trustees are closely monitoring the financial position. The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

The Trustees consider that there is a reasonable expectation that The Charity has sufficient resources to continue operating for the foreseeable future. For this reason, they continue to adopt the going-concern basis

of accounting in preparing the accounts.

OBJECTIVES FOR 2021-22

During the summer of 2020, it became clear that the COVID-19 crisis would have a significant and enduring impact on the community and on The Charity. We've responded with a scaled down, modified strategy to maximise our impact and support those in need, despite reduced resources, and at the same time start to lever long-term change. Our priority objectives for the year are:

• We'll drive the Best Care Everywhere across the UK, including sharing real-time experience and care during and beyond the pandemic.

• We'll mobilise Voices for Change, sharing evidence and platforms so passion and experience is amplified to support those affected, raise funds and drive progress.

• We'll harness the Power of Data to accelerate research, tackle inequality, empower choices, inform change and maximise our impact.

PLANS FOR THE FUTURE

Our goals remain unchanged, to defeat brain tumours. While the pandemic continues to have a global impact, the situation in the UK and many other countries is stabilising and improving through the vaccine programmes. In this back drop our immediate plans for 2021-22 are to return The Charity to growth. Growth in income and activities as stated above in the objectives for 2021-22. If circumstances and finances allow, we'll prepare plans for new rounds of research expenditure, either for the second half of 2021-22 or in 202223 and for each year thereafter.

We'll return to working on our new strategy, to build on the successes of our last five-year strategy, Defeating Brain Tumours, and this will guide our plans for future years.

We're also planning on developing and extending the reach of the technology underlying our app and databank, BRIAN (Brain tumouR Information and Analysis Network). This would include creating a separate product that could provide commercial opportunities by offering it to other charities.

33

THANKS

Last year, The Charity continued to fund our existing commitments to highest quality research, raise awareness and support thousands of people affected by a brain tumour. This work is only possible due to the unwavering commitment of our supporters and the companies, charitable trusts and foundations, both in the UK and internationally, which continue to work with us. To everyone involved, we cannot thank you enough for continuing this vital help in the most challenging of years.

In addition to the donors named below, we would like to thank all our anonymous donors.

TRUSTS

BBC Children in Need DWF Foundation Garfield Weston Foundation St James’s Place Charitable Foundation The AOK Trust The Colin Oliphant Charitable Trust The Eveson Charitable Trust The National Lottery Community Fund Coronavirus Community Support Fund The Peter Stebbings Memorial Charity The Syncona Foundation The William Brake Foundation

Lloyds Bank: Mid Corporates Team (Midlands) Mulberry Marketing Communications Salesforce Thunderhead Underbelly We Got Tickets

CO-FUNDING PARTNERS

Action Medical Research Great Ormond Street Hospital Children’s Charity Cancer Research UK Worldwide Cancer Research Children with Cancer UK

FAMILY-LED CHARITY PARTNERS

The Brian Cross Memorial Trust The Katy Holmes Trust The Oli Hilsdon Foundation OSCAR’s Paediatric Brain Tumour Charity

CORPORATES

Allports Group Baked In BECG Benesys Box of Hugs London BlueCube Technology Solutions Capital Group CDM London Childs Farm Clicky Media Decanter DHL Express Americas DWF Law Federated Hermes Future plc GoodStuff HSBC Joelson Knight Security Group K&L Gates

HIGH PROFILE SUPPORTERS

Alastair Stewart OBE Dominic Matteo Earl Spencer Ella and Matt Mills (Deliciously Ella) Guy Opperman MP Hal Cruttenden Holly Matthews Jason Durr James Jordan Jess Mills Jonny Wilkinson CBE Ian Chillcott Liam Conlon Lewis Moody OBE and Annie Moody Lorraine Kelly OBE Marc Silk Matt Allwright Mel Giedroyc The Neales Nick Baines (Peanut – Kaiser Chiefs) Nicki Chapman Olivia Colman CBE Owain Arthur Philippa Forrester Russell Watson Sandy Lyle MBE Sherrie Hewson

34

Sian Reese-Williams Steve Backshall Tcheky Karyo Tim Burgess and The Charlatans Tom Daley

We’d also like to thank the actress and writer Dawn French, one of The Charity’s first patrons and friend of Angela and Neil Dickson. Dawn has supported The Charity for over 20 years and continues to offer auction prizes and practical support wherever possible.

President

Professor Sir Colin Blakemore

Chief Executive Officer

Sarah Lindsell (resigned 31/03/2021) David Jenkinson (Interim CEO appointed 01/04/2021)

Company Secretary

Liam Heffernan

Charity Registration Numbers

TRUSTEES AND GOVERNANCE

Trustees

Jack Morris CBE (Chair) Neil Dickson MBE (Vice Chair) Graham Lindsay (Vice Chair) Dr. Elena Bechberger (appointed 17/09/2020) Angela Dickson MBE (resigned 17/09/2020) Dr. Rachel Edgar (appointed 10/12/2020) Simon Hay Sean Hird (appointed 10/12/2020) Justine Mcllroy Philippa Murray Berendina Norton Graham Norton Professor Alan Palmer Robert Posner (resigned 18/09/2020) Beth Worrall

England and Wales 1150054 Scotland SC045081

Principal and Registered Office

Fleet 27, Rye Close, Fleet, Hampshire GU51 2UH

Auditors

Menzies LLP Centrum House, 36 Station Road, Egham, Surrey TW20 9LF

Bankers

Lloyds Bank Plc, 147 High Street, Guildford GU1 3AG

Investment Managers

Albert E. Sharpe, 7 Elm Court Arden Street, Stratford-upon-Avon Smith and Williamson, 25 Moorgate, London

35

RESEARCHERS IN OUR COMMUNITY

As well as members of our Scientific Advisory Board (mentioned on page 37), these are just some of the researchers providing an ongoing contribution to our success.

Adam Waldman Adel Samson Adrian Bracken Al Yung Alex Bullock Andrew Peet Anthony Byrne Anthony Chalmers Antony Michalski Barry Pizer Bob Brown Catherine McBain Chris Jones Colin Kennedy Colin Watts Conor Mallucci Darren Hargrave David Jones David Walker

Denise Sheer

Diane Puccetti Eric Aboagye Federico Roncaroli Filomena Maggino Gelareh Zadeh Gregor Hutter Ian Waddell Jan Schuemann JP Martinez-Barbera Katie Bushby Keyoumars Ashkan Laure Bihannic Linda Dirven Linda Sharp Louis Chesler Lucy Stead Maggie Watson Marion Smits Mark Gilbert Martin Taphoorn Martin van den Bent Matt Williams Michael Hawkins Michael Jenkinson Michael Taylor Michael Vogelbaum

36

Dr Gerry Thompson Professor Nicola Sibson

Monika Heki Neil Carragher Ola Rominiyi Olivier Ayrault Pamela Kearns Paul Brennan Paul Northcott Paula Croal Phedias Diamandis Philipp Euskirchen Pim French Rachel Cox Rameen Beroukhim Richard Gilbertson Roel Verhaak Roger Packer Russ Hagen Sebastian Brandner Sebastien Serres Siddhartha Mitra Simon Bailey Simona Parrinello Sophie Thomas Spencer Watson Stefan Pfister Steve Pollard Steven Clifford Stuart Allan Stuart Smith Susan Picton Susan Short Terri Armstrong Thomas Wurdinger Todd Hankinson Tyler Miller Veronica Rendo Victor Levin Vincenzo D’Angiolella

BIOMEDICAL SCIENTIFIC ADVISORY BOARD

Name

Professor Richard Gilbertson Professor Steve Clifford Dr Mark Gilbert Dr David Adams Dr Susan Chang Dr Cynthia Hawkins Dr Paul Northcott Professor Simona Parrinello Professor Colin Watts Dr Duane Mitchell Professor Rick Livesey Dr Marcel Kool Dr Lucy Stead

Institution

The Cambridge Cancer Centre, UK The Institute of Child Health, Newcastle University, UK National Institutes of Health (NIH), USA The Wellcome Trust Sanger Institute, UK University of California San Francisco, USA The Hospital for Sick Children, Canada St Jude Children’s Research Hospital, USA University College London (UCL), UK University of Birmingham, UK University of Florida, USA University College London (UCL), UK German Cancer Research Centre, Germany University of Leeds, UK University of Edinburgh, UK University of Oxford, UK

CANNABINOID CLINICAL TRIAL SAB

Name

Dr Susan Chang Dr Annette Molinaro Dr Jeffrey Wefel Professor Martin van den Bent Dr Mark Gilbert

Institution

University of California, San Francisco, USA University of California, San Francisco, USA The University of Texas MD Anderson Cancer Center, USA Erasmus MC Cancer Center, The Netherlands National Institutes of Health (NIH), USA

Lay advisors Ms Christina Brincat Mrs Deborah Crossan Mrs Rachel Rathbone Ms Louise Webber-Edwards Mr John Graham

37

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Brain Tumour Charity is a registered charity, number 1150054, which was incorporated on 24 October 2012 and is governed by its memorandum of association.

When a vacancy occurs on the Board of Trustees, the Board will take the opportunity to review the skills matrix of Trustees, to identify specific skill sets that would strengthen the Board’s overall effectiveness. In addition, consideration is given to whether there is a need for any specific community or stakeholder group that needs to be represented by a new Trustee. The Board operates an equal opportunities recruitment policy and Trustees that are recruited are required to have demonstrable experience in the areas identified by the skills review.

Induction information covering the role and responsibilities of Trustees are provided to the Trustees and governance updates are provided as and when appropriate. The Trustees who served during the year are listed above.

The Trustees meet as a full Board four times per year and agree the broad strategy and areas of activity for The Charity including research strategy, approval of research grants, information and support strategy, financial planning, fundraising, investment, reserves and risk management policies and performance. All Trustees give of their time freely and no Trustee remuneration was paid in the year. Details of Trustee expenses are disclosed in Note 7 to the accounts. Trustees are required to disclose all relevant interests and register them with the Chief Executive and, in accordance with The Charity’s policy, withdraw from decisions where a conflict of interest arises.

Day-to-day operations and management are delegated to the Chief Executive and Senior Leadership Team who provide regular reports to the Trustees on performance and operations.

The Charity benefits from six committees which have been established to advise on key areas of activity, which are:

• Finance

• Research & Databank

• Information and Support

• Governance and Ethics

• Equality, Diversity and Inclusion

• Remuneration

The Charity has formed two Scientific Advisory Boards (SABs) to ensure that we only fund the highest quality research. Further details of the Biomedical Scientific Advisory Board (Biomed SAB) and the (Cannabionoid Clinical Trail SAB) can be found on page 33, set out under ‘Governance’.

EQUALITY, DIVERSITY AND INCLUSION

The Charity is committed to enhancing equality, diversity and inclusion, both within all areas of the organisation and in The Charity’s work and objectives, ensuring we represent and help the whole community we serve.

To expand on this long standing goal, in December 2020 the Trustees decided to form a standing committee looking at equality, diversity and inclusion across The Charity. The new committee to comprise of at least two members of the Executive team and two Trustees along with other members as required. The purpose of the committee is to make The Charity more proactive in reducing disparities, enhancing consistency of effort, raising awareness as well as evidencing and reporting on progress.

Progress is being made in numerous areas, with a focus on ensuring we're collecting appropriate and accurate information to measure where things are being done well and where improvements are required. For example patient surveys are being adapted to offer participants the option to complete details of their background from which we may be able to draw better insights on disparities in care.

38

GRANT-MAKING POLICY

The Charity has established its grant-making policy to achieve its objectives for the public benefit to improve the lives of people diagnosed with a brain tumour, to advance scientific research into the disease and to seek a permanent cure or cures in the future.

The Brain Tumour Charity funding opportunities are based on the key aims of our research strategy ‘A Cure Can’t Wait’ as we aim to double survival and halve the harm caused by brain tumours. We fund research into a wide variety of brain tumour types that affect both adults and children. We issue open calls for applications for project grants, programme grants and clinical trials.

More than 12,000 people are diagnosed with a primary brain tumour each year and over 5,000 lose their lives. Brain tumours are the biggest cancer killer of children and adults under 40.

The beneficiaries of our grant-making programme are ultimately people with brain tumours and their families and carers. We know that only research can make a difference in helping us understand how the disease develops, what causes it and how we might develop new treatments to improve outcomes for people with brain tumours.

The Charity invites applications for research grants from institutions by advertising in specialist publications and through the brain tumour and wider cancer networks. As a member of the Association of Medical Research Charities, we seek to follow best practice in retaining the independence of research funding and ensuring that successful applicants and research institutions abide by best practice in research ethics.

Research grants are funded on an annual basis to undertake an agreed programme of research. Continuation of the grants is subject to annual assessment by our Research Team, supported by our Scientific Advisory Board and Research & Databank Committee. In all cases, continuation of funding is subject to the research undertaken continuing to be in the interests of our beneficiaries and a progress assessment that is satisfactory.

APPROACH TO FUNDRAISING

The Charity is a member of the Fundraising Regulator, who holds the Code of Fundraising Practice for the UK.

Our approach is to ensure that we comply with the standards as set out in the Code across all of our fundraising activity. We did not engage with any third party fundraisers during the year. We comply with the key principles and behaviours of the Code to ensure that any vulnerable persons are treated fairly. All staff go through mandatory training when they join The Charity.

We received no complaints this year relating to fundraising.

There have been no breaches of the code of practice during the year.

39

STATEMENT OF THE TRUSTEES’ RESPONSIBILITIES

The Trustees (who are also directors of The Brain Tumour Charity for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including FRS 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland.

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of The Charity and the Group and of the incoming resources and application of resources, including the income and expenditure of the Group for that period. In preparing these financial statements, the Trustees are required to:

• Select suitable accounting policies and then apply them consistently

• Observe the methods and principles in the Charities SORP.

• Make judgements and estimates that are reasonable and prudent.

• State whether applicable UK Accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.

• Prepare the financial statements on the going-concern basis unless it is inappropriate to presume that The Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain The Charity’s transactions and disclose with reasonable accuracy at any time the financial position of The Charity and the Group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of The Charity and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as we are aware:

• There is no relevant audit information of which the charitable company's auditor is unaware.

• The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees Report (including the Strategic Report) was approved and authorised for issue by the Trustees on 27 September 2021 and signed on their behalf by:

Jack Morris CBE Chair of Trustees

40

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE BRAIN TUMOUR CHARITY

OPINION

We have audited the financial statements of The Brain Tumour Charity (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 March 2021 which comprise the Consolidated statement of financial activities, the Consolidated balance sheet, the Company balance sheet, the Consolidated statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

• give a true and fair view of the state of the Group's and of the parent charitable company's affairs as at 31 March 2021 and of the Group's incoming resources and application of resources, including its income and expenditure for the year then ended;

• have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

• have been prepared in accordance with the requirements of the Companies Act 2006.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

41

OTHER INFORMATION

The other information comprises the information included in the Annual report other than the financial statements and our Auditors' report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion, based on the work undertaken in the course of the audit:

• the information given in the Trustees' Report and Strategic Report for the financial year for which the financial statements are prepared are consistent with the financial statements.

• the Trustees' Report and Strategic Report have been prepared in accordance with applicable legal requirements.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report or Strategic Report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 requires us to report to you if, in our opinion:

• the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or

• the parent charitable company financial statements are not in agreement with the accounting records and returns; or

• certain disclosures of Trustees' remuneration specified by law are not made; or

• we have not received all the information and explanations we require for our audit: or

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

42

AUDITORS' RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

• The charitable company is subject to laws and regulations that directly affect the financial statements including financial reporting legislation. We determined that the following laws and regulations were most significant including the Companies Act 2006, Charities Act 2011, Employment and Health and Safety legislation, GDPR and the UK Code of Fundraising Practice. We assessed the extent of compliance with these laws and regulations as part of our procedures on the related financial statement items.

• We understood how the charitable company is complying with those legal and regulatory frameworks by, making inquiries to management, those responsible for legal and compliance procedures and the company secretary. We corroborated our inquiries through our review of board minutes.

• The engagement partner assessed whether the engagement team collectively had the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations. The assessment did not identify any issues in this area.

• We assessed the susceptibility of the charitable company’s financial statements to material misstatement, including how fraud might occur. Audit procedures performed by the engagement team included:

• Identifying and assessing the design effectiveness of controls management has in place to prevent and detect fraud;

• Understanding how those charged with governance considered and addressed the potential for override of controls or other inappropriate influence over the financial reporting process;

• Challenging assumptions and judgments made by management in its significant accounting estimates; and

• Identifying and testing journal entries, in particular any journal entries posted with unusual account combinations.

• As a result of the above procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the following areas:

• Posting of fraudulent journal entries

• Posting of fraudulent payments and receipts in the accounting software

• Authorisation, processing, and payment of fraudulent expenses

• Fictitious employees

• Timing of revenue recognition

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' report.

43

USE OF OUR REPORT

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.

Janice Matthews FCA (Senior statutory auditor)

for and on behalf of

Menzies LLP

Chartered Accountants Statutory Auditor Centrum House 36 Station Road Egham Surrey TW20 9LF

Date: 27-09-2021

44

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

Consolidated Statement of Financial Activities for the year ended 31 March 2021

Unrestricted Funds Restricted Funds Notes £'000 £'000 Income and Expenditure Income from: Donations and Legacies 3 6,577 1,180 Other Trading 171 15 Investments 355 - Total Income 7,103 1,195 Expenditure on: Raising Funds 1,742 2 Charitable Activities Research 5,405 1,239 Patient Support 1,724 371 Campaigning & Raising Awareness 829 20 Total expenditure on Charitable Activities 7,958 1,630 Total expenditure 4 9,700 1,632 Net income before gains and losses on investment assets (2,597) (437) Realised and Unrealised gains on investment assets 2,656 - Net income/(expenditure) 59 (437) Transfers (955) 955 Net movement in funds for the year (896) 518 Reconciliation of funds Balances at 1 April 2020 4,244 2,991 Balances at 31 March 2021 3,348 3,509	Total 2021 Unrestricted Funds Restricted Funds £'000 £'000 £'000 7,757 8,025 2,331 186 405 149 355 398 - 8,298 8,828 2,480 1,744 2,096 102 6,644 4,342 2,225 2,095 2,298 352 849 1,118 27 9,588 7,758 2,604 11,332 9,854 2,706 (3,034) (1,026) (226) 2,656 (1,561) - (378) (2,586) (226) - - - (378) (2,586) (226) 7,235 6,830 3,217 6,857 4,244 2,991	Total 2020 £'000 10,356 554 398
		11,308 2,197 6,567 2,650 1,146
		10,362
		12,560
		(1,252) (1,561)
		(2,813) - (2,813) 10,047
		7,235

The Statement of Financial Activities includes all gains and losses recognised in the year. All incoming resources and resources expended derive from continuing activities.

The notes on pages 48-63 form part of these financial statements.

45

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

Consolidated Balance Sheet at 31 March 2021

Company number: 08266522

Notes Fixed Assets Intangible Assets 10 Tangible Assets 11 Investment in Subsidiary 12 Investments 12 Current Assets Stock Debtors 13 Cash at Bank Creditors Amounts falling due within one year 14 Provision for liabilities 15 Net Current (Liabilities)/Assets Total Assets less Current Liabilities Funds General Reserve Designated funds Unrestricted funds Restricted Funds	Consolidated 2021 2020 £'000 £'000 34 57 281 14 - - 14,652 12,033 9 11 452 720 4,978 7,306 5,439 8,037 (13,449) (12,907) (100) - (8,110) (4,870) 6,857 7,235 1,752 2,500 1,596 1,744 3,348 4,244 3,509 2,991 6,857 7,235	Company 2021 2020 £'000 £'000 34 57 281 14 - - 14,652 12,033 - - 453 727 4,972 7,306 5,425 8,033 (13,456) (12,907) (100) - (8,132) (4,875) 6,836 7,230 1,731 2,495 1,596 1,744 3,327 4,239 3,509 2,991 6,836 7,230	Company 2021 2020 £'000 £'000 34 57 281 14 - - 14,652 12,033 - - 453 727 4,972 7,306 5,425 8,033 (13,456) (12,907) (100) - (8,132) (4,875) 6,836 7,230 1,731 2,495 1,596 1,744 3,327 4,239 3,509 2,991 6,836 7,230
			8,033 (12,907) -
			(4,875)
			7,230
			2,495 1,744
			4,239 2,991
			7,230

The financial statements were approved by the trustees on 27[th] September 2021 and signed on their behalf by:

………………………………….....

Jack Morris CBE Chair of Trustees

………………………………….....

Neil Dickson MBE Vice-Chair of Trustees

The notes on pages 48-63 form part of these financial statements.

46

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

Consolidated Cash Flow for the year ended 31 March 2021

2021	2021
Reconciliation of net income to net cash flow from operating activities Net income for the year Adjustments for: Depreciation Losses/ (Gains) on investments Income from Investments Provision for liabilities Loss/ (profit) on sale of fixed assets (Increase)/ decrease in stocks Decrease/ (increase) in Debtors Increase / (decrease) in Creditors Net cash (used in)/ provided by operating activities Statement of cash flows Cash flows from operating activities Net cash (used in)/ provided by operating activities Cash flows from investing activities: Dividends, interest and rents from investments Purchase of computer software Purchase of PP&E Sale/(purchase) of investments Net cash provided by/ (used in) investing activities Change in cash and cash equivalents in the year Balances at 1 April 2020 Balances at 31 March 2021 Analysis of cash and cash equivalents Cash in hand Notice deposits (less than 3 months) Total cash and cash equivalents Analysis of changes in net debt At 1 April 2020 Cash 2,275 Cash equivalents 5,031 Net debt 7,306		2021 £'000 (378) 50 (2,619) (355) 100 2 2 268 541 (2,388) 2021 £'000 (2,388) 355 - (296) - 59 (2,328) 7,306 4,978 2021 £'000 2,944 2,034 4,978 Other Cash flows 669 (2,997)	2020 £'000 (2,813) 49 1,611 (398) - - (2) 21 6 (1,526) 2020 £'000 (1,526) 389 (10) (1) 2,000 2,378 852 6,454 7,306 2020 £'000 2,275 5,031 7,306 At 31 March 2021 2,944 2,034
	7,306	(2,328)	4,978

47

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

Notes to the Financial Statements

1. Statement of compliance

These financial statements have been prepared in compliance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2016) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) and the Companies Act 2006.

The Brain Tumour Charity is a private company limited by guarantee registered in England and Wales under the Companies Act. The address of the registered office and company number are given on page 35. The principal activity of the company and the nature of its operations are set out in the trustees report starting on page 3.

2. Accounting Policies

(a) Basis of preparation of financial statements

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of investments at market value through the statement of financial activities.

The Brain Tumour Charity (“The Charity”) constitutes a public benefit entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the entity.

The results and balance sheet of The Charity’s subsidiary undertaking, TBTC Trading Ltd has been consolidated on a line by line basis. TBTC Trading Ltd prepares its accounts to 31 March.

In accordance with s408 of the Companies Act 2006, The Charity has not presented its unconsolidated statement of financial activities. The net outgoing resources for The Charity in the year were £394,000 (2020: £2,801,000).

The financial statements have been prepared under the historical cost convention.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant judgements

The judgements (apart from those involving estimations) that management has made in the process of applying the entity's accounting policies and that have the most significant effect on the amounts recognised in the financial statements are as follows:

Income recognition

In the recognition of income in accordance with the accounting policy the management consider the detailed criteria for the income recognition from its activities and, in particular, whether The Charity had entitlement to the funds.

Key sources of estimation uncertainty

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. The key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are as follows:

48

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

Full payment of our research grants is contingent upon the successful outcome of periodic reviews. Research expense is recognised in advance of each phase of individual projects and the outcome and final cost of projects can vary, depending on a number of uncertain factors.

Some of our legacy income is dependent on the outcome of future events, for example the sale of property. Where the value of a legacy can be estimated reliably at the balance sheet date, the value is recognised as income in the year. In addition we occasionally benefit from donated services, which we would otherwise have to purchase, these donations are valued and included as income and cost at the estimated price we would pay in the open market.

(b) Company status

The company was incorporated on 24 October 2012 as a company limited by guarantee. The members of the company are the trustees named on page 35. In the event of the company being wound up, the liability in respect of the guarantee is limited to £1 per member of the company.

(c) Income

All income is included in the Statement of Financial Activities when The Charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donations and fundraising events from private individuals and sponsors are taken into account on the basis of cash receipts. Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. Income tax recoverable is accounted for on the same basis as the income to which it relates. Bank interest and investment income is accounted for on an accruals basis.

Government grants received as a result of the Coronavirus Job Retention scheme are recognised as income when the charity is entitled to the money.

Income which is material either because of its size or nature, or which is non-recurring, is treated as exceptional. Exceptional income is excluded in our underlying income.

(d) Expenditure

All expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year-end are noted as a commitment, but not accrued as expenditure.

Direct costs, including directly attributable salaries, are allocated on an actual basis to the key strategic areas of activity. Overheads and other salaries are allocated between the expense headings on the basis of time spent. Termination payments are accounted for when notice has been given to the employees concerned.

Support costs are those costs incurred directly in support of expenditure in the objects of The Charity and are allocated to activities on a consistent basis.

Governance costs are those incurred in connection with enabling The Charity to comply with external regulation, constitutional and statutory requirements and in providing support to the trustees in the discharge of their statutory duties.

Employee Termination Benefits are accounted for when notice is given to the employee concerned.

49

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

(e) Stocks

Stock is measured at the lower of cost and net realisable value.

(f) Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of The Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by The Charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to unrestricted funds unless they are generated from investing a specific endowment.

(g) Fixed assets

Intangible fixed assets comprise computer software purchased from third parties as well as related external development costs. Computer software costs are amortised on a straight-line basis over the estimated useful lives of the software, from the date the software is available for use.

Tangible fixed assets are shown at purchased cost, together with incidental expenses of acquisition. Tangible fixed assets under £1,000 are not capitalised. Fixed assets are depreciated on a straight-line basis over their estimated useful lives.

(h) Estimated useful lives

The estimated useful lives of fixed assets are as follows:

Computer equipment	3 years
Office equipment	5 years
Leasehold improvements	the lease term
Computer software	5 years

(i) Investments

Investments are revalued at fair value at the balance sheet date and any unrealised gain or loss is taken to the Statement of Financial Activities. Investments are intended to be available for use by The Charity in its charitable activities.

(j) Donated Assets and Services

Where services or assets are provided to The Charity as a donation that would normally be purchased from suppliers, this contribution is included in the financial statements at an estimate based on the value of the contribution to The Charity.

(k) Operating lease

The Charity classifies the lease of Fleet 27 as an operating lease. Rental charges are provided over the term of the lease (15 years).

(l) Pensions

The charitable company operates a defined contributions pension scheme. The scheme is funded partly by contributions from the employees and from The Charity. Such contributions are held and administered completely independent of the charitable company's finances. The contributions are made by The Charity and are accounted for on an accruals basis.

50

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

(m) Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

(n) Going concern

No material uncertainties that may cast significant doubt about the ability of The Charity to continue as a going concern have been identified by management or the trustees.

The COVID-19 pandemic began to impact in March 2020 and continued to affect the entire financial year, having an impact on the Charity’s income through fundraising from mass participation events such as sponsorship of marathon particpants or holding of physical fundraising events. It impacted on the daily activities of the Charity as employees had to work remotely. It also created volatility in the book value of financial investments. The Charity was able to rapidly adapt to these changes, with systems that facilitated remote working, cost saving measures utilising the Coronavirus Job Retention Scheme and reducing headcount as well as adapting to virtual fundraising events. The Charity expects income will return to growth in the following twelve months, as the benefits of the vaccination programme reduce the effects of the pandemic. The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

The financial statements are accordingly prepared on the Going Concern basis.

3. Donations and legacies

Unrestricted £'000 Ordinary activities: Regular Giving 258 Donations, appeals and fundraising 5,352 Gift Aid 483 Legacies 155 Government Grants 329 6,577	Restricted £'000 41 1,120 18 - - 1,180	2021 Total Unrestricted Restricted £'000 £'000 £'000 299 221 14 6,472 6,437 2,270 501 576 46 155 791 1 329 - - 7,757 8,025 2,331	2020 Total £'000 235 8,707 622 792 -
			10,356

Government Grants consist of amounts received under the Government Coronavirus Job Retention Scheme.

51

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

4. Analysis of resources expended

Raising funds Charitable activities: Research Patient Support Campaigning and raising awareness Total expenditure on charitable activities Total expenditure Raising funds Charitable activities: Research Patient Support Campaigning and raising awareness Total expenditure on charitable activities Total expenditure	Direct Costs £'000 1,579 1,167 2,019 769 3,955 5,534 Direct Costs £'000 2,083 1,711 2,573 955 5,238 7,321	Grants £'000 - 5,446 - - 5,446 5,446 Grants £'000 - 4,820 - - 4,820 4,820	Support Costs £'000 165 31 76 80 187 353 Support Costs £'000 114 36 77 191 305 419	2021 Total £'000 1,744 6,644 2,095 849
				9,588
				11,332
				2020 Total £'000 2,197 6,567 2,650 1,146
				10,362
				12,560

5. Research grant cost analysis

Research programmes Research projects Clinical trials Fellowships Conferences	2021 £'000 4,406 831 155 54 - 5,446	2020 £'000 2,967 1,333 444 66 10
		4,820

A breakdown of research costs by individual award is provided in note 22.

6. Support costs by activity

Finance and Human resources £'000 Raising funds 53 Charitable activities: Research 10 Patient Support 25 Campaigning and raising awareness 26 2021 Total 114	Central facilities Information technology Central management Governance £'000 £'000 £'000 £'000 19 38 17 38 4 7 3 7 9 17 8 17 9 19 8 18 41 81 36 80	Total £'000 165 31 76 80
		353

52

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

Finance and Human resources £'000 Raising funds 32 Charitable activities: Research 10 Patient Support 22 Campaigning and raising awareness 54 2020 Total 119	Central facilities Information technology Central management Governance £'000 £'000 £'000 £'000 16 32 9 25 5 10 3 8 11 22 6 17 26 54 15 41 58 117 34 91	Total £'000 114 36 77 191
		419

7. Governance costs

Auditor's remuneration Trustee meetings Legal and professional fees Staff	2021 £'000 20 - 3 57 80	2020 £'000 15 2 2 72
		91

Trustees received no remuneration (2020: £nil). One trustee was reimbursed for travel expenses in the year totalling £26 (2020: one for £325). The premium in respect of professional liability insurance covering trustee indemnity was £nil (2020: £nil).

8. Staff costs

Staff costs
Wages and salaries Social security costs Pension	2021 £'000 3,402 311 296 4,009	2020 £'000 3,704 338 228
		4,272

Wages and salaries Social security costs Payments to defined contribution pension plans	Group 2021 2020 £'000 £'000 3,402 3,704 311 338 296 228 4,009 4,272	Company 2021 2020 £'000 £'000 3,402 3,704 311 338 296 228 4,009 4,272	Company 2021 2020 £'000 £'000 3,402 3,704 311 338 296 228 4,009 4,272
			4,272

During the year redundancy payments were made totalling £29,000 (2020: £6,000). At 31 December 2021 there was £nil provided (2020 £nil).

The average number of employees during the year was 108 (2020: 118).

The number of employees whose total employee benefits (excluding employer pension costs) amounted to over £60,000 in the year were as follows:

53

The Brain Tumour Charity

Annual Report and Financial Statements for the Year Ended 31 March 2021

	2021	2020
£60,001 - £70,000	1	2
£70,001 - £80,000	1	1
£80,001 - £90,000	1	1
£90,001-£100,000	-	1

Total employment costs of the Senior Leadership Team who are considered to be the key management personnel of The Charity was £572,000 (2020: £759,000).

9. Taxation

The Brain Tumour Charity is a registered charity and all of its activities fall within the exemptions afforded to charities under taxation legislation. TBTC Trading Ltd donates its net trading profit to The Brain Tumour Charity and accordingly has no taxable income. No charge to taxation therefore arises.

10. Intangible fixed assets

Group and Company

	Computer Software
	£'000
Cost
At 1 April 2020	162
Additions	-
At 31 March 2021	162
Depreciation
At 1 April 2020	104
Charge for the year	24
At 31 March 2021	128
Net book value
At 31 March 2021	34
At 31 March 2020	57

54

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

11. Tangible fixed assets

Group and Company

Leasehold Improvements £'000 Cost At 1 April 2020 63 Additions 289 Disposals (63) At 31 March 2021 289 Depreciation At 1 April 2020 59 Charge for the year 17 Disposals (61) At 31 March 2021 14 Net book value At 31 March 2021 274 At 31 March 2020 4	Computers and Office Equipment £'000 161 7 - 168 151 10 - 161 7 10	Total £'000 223 296 (63)
		456
		210 27 (61)
		175
		281
		14

12. Investments

(a) Subsidiary Investment

Cost at 1 April 2020 and 31 March 2021

£ 100

The Charity owns 100% of the £1 ordinary share capital of TBTC Trading Ltd, a company incorporated in England and Wales, company number 08855559. The business activity of TBTC Trading Ltd is retailing.

At 31 March 2021 the aggregate of the share capital and reserves of TBTC Trading Ltd was £21,000 (2020: £4,000).

The net profit of TBTC Trading Ltd consolidated in to these accounts, as set out below, will be donated to The Brain Tumour Charity.

Turnover Cost of sales Gross profit Other operating expenses Profit before donation Donation Retained profit/ (loss)	2021 £'000 49 (12) 37 (16) 21 (4) 17	2020 £'000 53 (16)
		37 (33)
		4 (16)
		(12)

Cost of sales represent cost of stock sold in the year.

At 31 March 2021 the aggregate assets of TBTC Trading Ltd were £24,000 (2020: £20,000), aggregate liabilities £3,000 (2020: £16,000) and shareholder’s funds £21,000 (2020: £4,000).

55

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

(b) General Investments

Group and Company At 1 April Additions at cost Disposals Net unrealised (loss) on revaluation At 31 March Historical Cost Investments at market value comprised: UK Equities Overseas Equities Absolute return funds Multi asset funds Alternative investments Fixed income securities Cash held within the investment portfolios Accrued income At 31 March 2021	2021 £'000 12,033 1,464 (4,541) 5,696 14,652 12,204 2021 £'000 3,775 3,539 442 234 578 3,184 2,900 - 14,652	2020 £'000 15,635 1,030 (2,830) (1,802)
		12,033
		14,258
		2020 £'000 2,662 2,418 404 241 791 5,410 99 9
		12,033

During the year income from listed investments was £350,000 (2020: £371,000) and interest on deposits £4,000 (2020: £27,000).

13. Debtors

Trade debtors Accrued income and prepayments Other debtors Amounts owed by TBTC Trading Ltd	Consolidated 2021 2020 £'000 £'000 74 181 353 381 26 158 - - 453 720	Company 2021 2020 £'000 £'000 74 181 353 374 26 158 - 14 453 727	Company 2021 2020 £'000 £'000 74 181 353 374 26 158 - 14 453 727
			727

56

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

14. Creditors

Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. In the year to 31 March 2021 £297,000 (2020: £243,000) of income was deferred and £97,000 (2020: £331,000), brought forward from previous periods, was released.

Grants payable Accruals and deferred income Trade Creditors Other creditors Social Security and other taxes Amounts owed to TBTC Trading Ltd	Consolidated 2021 2020 £'000 £'000 12,293 11,647 468 307 593 815 28 42 67 96 - - 13,449 12,907	Company 2021 2020 £'000 £'000 12,294 11,647 465 305 593 816 28 42 67 97 9 - 13,456 12,907	Company 2021 2020 £'000 £'000 12,294 11,647 465 305 593 816 28 42 67 97 9 - 13,456 12,907
			12,907

15. Provision for liabilities

At 1 April 2020 Additions Disposals At 31 March 2021	Consolidated 2021 2020 £'000 £'000 - - 100 - - - 100 -	Company 2021 2020 £'000 £'000 - - 100 - - - 100 -

The provision related to the future cost of obligations under the terms of a property operating lease at Fleet 27.

16. Research commitments

At 31 March 2021 The Charity had authorised commitments that were subject to outstanding conditions amounting to £13,586,000 (2020: £14,802,000), these are expected to fall due as follows:

Within one year Between one and two years Between two and three years Between three and four years Between four and five years Five years and further	2021 £'000 5,736 3,609 2,546 1,283 133 279 13,586	2020 £'000 5,762 4,278 2,598 1,833 85 246
		14,802

57

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

17. Operating lease commitments

The total of future minimum property lease payments on operating leases are as follows:

Within one year Between one and five years	Consolidated 2021 2020 £'000 £'000 143 6 1,242 - 1,385 6	Company 2021 2020 £'000 £'000 143 4 1,242 - 1,385 4	Company 2021 2020 £'000 £'000 143 4 1,242 - 1,385 4
			4

Operating lease charges during 2021 were £30,000 for property (2020: £102,000).

18. Analysis of net assets between funds

Intangible fixed assets Tangible fixed assets Investments Other current assets Current liabilities Intangible fixed assets Tangible fixed assets Investments Other current assets Current liabilities	Unrestricted Funds £'000 34 281 14,652 (1,572) (10,047) 3,348 Unrestricted Funds £'000 57 14 12,033 2,240 (10,101) 4,243	Restricted Funds £'000 - - - 7,011 (3,503) 3,509 Restricted Funds £'000 - - - 5,798 (2,807) 2,991	Total 2021 £'000 34 281 14,652 5,439 (13,549)
			6,857
			Total 2020 £'000 57 14 12,033 8,037 (12,907)
			7,235

58

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

19. Funds

Consolidated At 1 April 2020 Incoming Resources £'000 £'000 Restricted funds: Research funds 684 635 Everest Fund 1,395 36 Awareness funds 392 6 Support funds 520 518 2,991 1,194 Unrestricted funds: General reserve 2,499 6,244 Designated funds 1,744 859 4,243 7,103 7,235 8,298 Company At 1 April 2020 Incoming Resources £'000 £'000 Restricted funds: Research funds 684 635 Everest Fund 1,395 36 Awareness funds 392 6 Support funds 520 518 2,991 1,194 Unrestricted funds: General reserve 2,495 6,195 Designated funds 1,744 859 4,239 7,054 7,230 8,248	Resources Expended £'000 (294) (945) (15) (378) (1,631) (8,693) (1,007) (9,700) (11,332) Resources Expended £'000 (294) (945) (15) (378) (1,631) (8,665) (1,007) (9,672) (11,303)	Fund Transfers Investment Gains At 31 March 2021 £'000 £'000 £'000 1,031 - 2,056 - - 486 - - 383 (77) - 584 955 - 3,509 (955) 2,656 1,752 - - 1,596 (955) 2,656 3,348 - 2,656 6,857 Fund Transfers Investment Gains At 31 March 2021 £'000 £'000 £'000 1,031 - 2,056 - - 486 - - 383 (77) - 584 955 - 3,509 (950) 2,656 1,731 - - 1,596 (950) 2,656 3,327 4 2,656 6,836	Fund Transfers Investment Gains At 31 March 2021 £'000 £'000 £'000 1,031 - 2,056 - - 486 - - 383 (77) - 584 955 - 3,509 (955) 2,656 1,752 - - 1,596 (955) 2,656 3,348 - 2,656 6,857 Fund Transfers Investment Gains At 31 March 2021 £'000 £'000 £'000 1,031 - 2,056 - - 486 - - 383 (77) - 584 955 - 3,509 (950) 2,656 1,731 - - 1,596 (950) 2,656 3,327 4 2,656 6,836
			3,509
			1,731 1,596
			3,327
			6,836

59

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

Consolidated At 1 April 2019 Incoming Resources £'000 £'000 Restricted funds: Research funds 321 1,273 Everest Fund 2,214 167 Awareness funds 371 50 Support funds 311 989 3,217 2,480 Unrestricted funds: General reserve 5,552 7,804 Designated funds 1,278 1,024 6,830 8,828 10,047 11,307 Company At 1 April 2019 Incoming Resources £'000 £'000 Restricted funds: Research funds 321 1,273 Everest Fund 2,214 167 Awareness funds 371 50 Support funds 311 989 3,217 2,480 Unrestricted funds: General reserve 5,535 7,751 Designated funds 1,278 1,024 6,814 8,775 10,031 11,254	Resources Expended £'000 (1,261) (986) (29) (430) (2,706) (9,282) (571) (9,854) (12,560) Resources Expended £'000 (1,261) (986) (29) (430) (2,706) (9,234) (571) (9,805) (12,511)	Fund Transfers Investment Gains At 31 March 2020 £'000 £'000 £'000 350 - 684 - - 1,395 - - 392 (350) - 520 - - 2,991 (13) (1,561) 2,499 13 - 1,744 - (1,561) 4,243 - (1,561) 7,235 Fund Transfers Investment Gains At 31 March 2020 £'000 £'000 £'000 350 - 684 - - 1,395 - - 392 (350) - 520 - - 2,991 3 (1,561) 2,495 13 - 1,744 16 (1,561) 4,239 16 (1,561) 7,230	Fund Transfers Investment Gains At 31 March 2020 £'000 £'000 £'000 350 - 684 - - 1,395 - - 392 (350) - 520 - - 2,991 (13) (1,561) 2,499 13 - 1,744 - (1,561) 4,243 - (1,561) 7,235 Fund Transfers Investment Gains At 31 March 2020 £'000 £'000 £'000 350 - 684 - - 1,395 - - 392 (350) - 520 - - 2,991 3 (1,561) 2,495 13 - 1,744 16 (1,561) 4,239 16 (1,561) 7,230
			2,991
			2,495 1,744
			4,239
			7,230

Purpose of restricted funds

Research funds

Everest fund

Awareness funds

Support funds

Research funds comprise income which is restricted to expenditure on research, an analysis of research expenditure by award is provided in note 22. During 2015/16 we received exceptional income of £2,889,949 which is restricted to funding research into paediatric low grade brain tumours. During 2016/17 we launched our investment in The Everest Centre for Research into Paediatric Low Grade Brain Tumours. Awareness funds comprise income which is restricted to raising awareness of brain tumours across the UK. Our current campaign is HeadSmart: be brain tumour aware. Support funds comprise funds raised and used to provide support to individuals and families affected by brain tumours through the operation of a helpline, support groups and networks, responding to email enquiries and any other activities that may be beneficial to those affected.

60

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

Designated Funds represent accumulated net income raised by our Supporter Groups where they have expressed a preference over how the funds they raise should be spent. Supporter Group preferences typically include our research and support activities. In addition, approved funding of a Chair position at a UK university has also been classed as designated funds.

Fund transfers represent transfers between funds to apply income raised to specific causes for the Lewis Moody Foundation or to reallocate expenses that had been over-allocated to restricted funds back to unrestricted funds.

20. Related parties

The Charity owns 100 of the issued £1 ordinary shares of TBTC Trading Ltd, a company with the same registered address as The Charity. TBTC Trading Ltd acts as a sales agent on behalf of The Charity. At 31 March 2021 The Charity owed TBTC Trading Ltd £9,444 (2020: TBTC Trading owed The Charity £14,058).

Trustees, their close family members and entities they control, made donations to The Charity totalling £16,783 during the year (2020: £771,205) and paid contributions totalling £nil (2020: £595) during a number of our fundraising events.

21. Grants receivable

During the year The Charity received support from the following trusts and foundations, where donations were restricted or designated to specific areas of activity as follows:

Trust and foundation	£'000	Charitable activity
Peter Stebbings Memorial Charity	8	ET 2019/2 - Brandner - UCL
Garfield Weston Foundation	75	BRIAN Databank
The National Lottery Community Fund		Coronavirus Community
Coronavirus Community Support Fund	89	Support Fund

61

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

22. Research awards

Programme - Hochhauser - UCL - SDBCU Programme - Chesler - ICR - Medullo Super enhancers Programme - Pollard - University Edinburgh - Chromatin targets in GBM Programme - Jones - DKFZ - Everest Centre Programme - Kennedy - University Southampton - PNET5 QoL Programme - Wurdinger - VU Amsterdam - WINDOW Programme - Zadeh - University Health Network - Clinically Aggressive Meningiomas Programme - Northcott - St Judes - MERIT Programme - Hankinson - University Colorado - Adamantinomous Craniopharyngioma Programme - Parrinello - UCL - Mapping Spatio-temporal heterogenity Programme - Gilbertson - CRUK Cambridge Cancer Institute- ST-EP-RELA and CPC Programme - Carragher - University Edinburgh - Therapeutic Combinations in GBM Project - Brennan - University Edinburgh - LG to HG transformation Project - Edinburgh - Brenan Development of a Novel Tumour-Targeting Thermogel activated by Matrix Metalloproteinases Project – Clark – UCL Neurocognitive effects of medullo Project - Kennedy - University Southampton - PROMOTE Clinical Trial - Mallucci - Alder Hey - NORDIC Project - Jones - ICR - Gene editing for DIPG - Billie Butterfly Fund Project - Rooney - University Edinburgh - BT LIFE Project - Sharp - Newcastle University - Self-supporting management for survivors Project - Bracken - Trinity College - EZH2 in DIPG Project - Stead - University Leeds - GBM Nanobiopsy Project - Smits - Erasmus Medical Centre - Mapping biomarkers with MRI Project - Serres - University Nottingham - STAT3 and hypoxia in GBM Project - Johns - Telethon Kids Institute - Ion channel drugs Project - Diamandis - University Health Network - AI to classify tumours Project - Hutter - University Basel - Microglial drug response in GBM bioreactors Project - D'Angiolella - University Oxford - Blocking MTAP in GBM Project - Northcott - St Judes - Refining medullo in USA clinical trials Project - van den Bent - Erasmus Medical Centre - Refining glioma classification in CATNON trial Project - Taphoorn - Leiden University Medical Centre - Defining Patient Reported Outcomes Project - Hawkins - Uni Birmingham - Combining child and YA data for better monitoring Project - Verhaak - Jackson Laboratory - ecDNA isolation and targeting in GBM Project - Schuemann - Massachusetts General Hospital - Extreme dose rate proton therapy Research awards sub-total carried forward	2021 £'000 - 306 317 945 43 387 300 291 216 339 238 578 - (73) (7) (73) (22) - - (28) - - - - - - - - - 100 18 43 140 - 56 4,114	2020 £'000 15 325 306 964 44 375 390 328 219 - - - (12) - - - - 51 86 - 98 34 23 65 72 66 58 59 61 99 160 - - 60 -
		3,946

62

The Brain Tumour Charity Annual Report and Financial Statements for the Year Ended 31 March 2021

Research awards sub-total brought forward Project - Hegi - Lausanne - MGMT methylation Project - Smith - Nottingham - RNA Methylation Project - Rominiyi - Sheffield - Ex-vivo 3D models Project - Cambridge - Hart Project - Bullock - SGC Oxford - ALK2/ACVR1 Kinase Inhibitors for DIPG Therapy Clinical Trial - Hargrave - University Birmingham - BIOMEDE Clinical Trial - Chalmers - University Glasgow - PARADIGM 2 Clinical Trial - Short - University Leeds - ReoGlio Clinical Trial - Kearns - University Birmingham - PNET5 CTU Clinical Trial - Walker - INTREPID Nottingham Clinical Trial - Michalski - Birmingham (9/120) Clinical Trial - HR-MB - Bailey - Newcastle Fellowship - Bihannic - St Jude - Origins of Groups 3 and 4 medullo QfCs 2019 - Chesler ICR QfCs 2019 - Beroukhim - Dana-Farber CB 2019/2 - Zadeh - UHN CB 2019/2 - Euskirchen - Charite Hospital ET 2019/2 - French -Erasmus ET 2019/2 - Brandner - UCL FL 2019 - Croal - Nottingham FL 2019 - Watson - Lausanne FL 2019 - Miller - Massachusetts FL 2019 - Rendo - Dana-Farber QoL 2019 - Byrne - Cardiff Conferences and workshops - Kennedy - Southampton Conferences and workshops - ReMission Summit Other	2021 £'000 4,114 - 60 - - - - - - 44 - - 111 54 338 195 96 101 60 56 36 60 60 60 88 - - (85) 5,446	2020 £'000 3,946 92 60 60 (11) 190 19 2 16 44 10 (17) 371 66 - - - - - - - - - - - 5 5 (37)
		4,820

23. Business Combination

During the year, the activities of Meningioma UK, a charity registered with The Scottish Charity Regulator were merged with those of The Brain Tumour Charity to improve services and outcomes for those affected by brain tumours. Assets totalling £5,375 were taken over by The Brain Tumour Charity and this combination is not accounted for as a formal merger.

63

thebraintumourcharity.org

Registered office: Fleet 27, Rye Close, Fleet, Hampshire, GU51 2UH

© The Brain Tumour Charity 2021. Registered Charity in England and Wales (1150054) and Scotland (SC045081).